BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

PMV’s $70 million series D round included multiple crossover investors, a sign the biotech will join the rush of preclinical companies lining up for an IPO this year. Crossover investors are the most prolific backers...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

A day after Arch and Flagship unveiled dueling billion dollar funds, venBio is staying the course with a more modest $394 million fund. What is new for the nine-year-old firm is a dramatic shift away...
BC Extra | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
BC Week In Review | Feb 2, 2018
Company News

Partner Therapeutics raises $60M, in-licenses Leukine

Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Feb. 1 in a series A round led by Perceptive Advisors and also gained rights to Leukine sargramostim from Sanofi (Euronext:SAN; NYSE:SNY). Fellow new investors...
BC Extra | Feb 2, 2018
Financial News

Partner Therapeutics raises $60M, in-licenses Leukine

Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Thursday in a series A round led by Perceptive Advisors and also gained rights to Leukine sargramostim from Sanofi (Euronext:SAN; NYSE:SNY). Fellow new investors Adams...
BC Extra | Feb 1, 2018
Company News

Roche halts SERD from Seragon, reports earnings

Roche (SIX:ROG; OTCQX:RHHBY) disclosed in its Thursday earnings report that it will discontinue development of RG6047 (GDC-0927). The selective estrogen receptor degrader was in a Phase I trial to treat ER-positive, HER2-negative metastatic breast cancer....
BC Extra | Jan 26, 2018
Company News

Management tracks: Partner Therapeutics, Merck

Robert Mulroy and Debasish Roychowdhury launched newco Partner Therapeutics Inc. (Boston, Mass.), which has a portfolio of approved and late-stage cancer therapies. Chairman and CEO Mulroy was co-founder, CEO and president of Merrimack Pharmaceuticals Inc....
BC Week In Review | Apr 28, 2017
Clinical News

RG6046: Development discontinued

Roche said it discontinued development of RG6046, which it gained through its acquisition of Seragon Pharmaceuticals Inc. in 2014. The pharma had studied RG6046 in a Phase II trial to treat estrogen receptor-positive, HER2-negative metastatic...
Items per page:
1 - 10 of 36
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

PMV’s $70 million series D round included multiple crossover investors, a sign the biotech will join the rush of preclinical companies lining up for an IPO this year. Crossover investors are the most prolific backers...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

A day after Arch and Flagship unveiled dueling billion dollar funds, venBio is staying the course with a more modest $394 million fund. What is new for the nine-year-old firm is a dramatic shift away...
BC Extra | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
BC Week In Review | Feb 2, 2018
Company News

Partner Therapeutics raises $60M, in-licenses Leukine

Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Feb. 1 in a series A round led by Perceptive Advisors and also gained rights to Leukine sargramostim from Sanofi (Euronext:SAN; NYSE:SNY). Fellow new investors...
BC Extra | Feb 2, 2018
Financial News

Partner Therapeutics raises $60M, in-licenses Leukine

Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Thursday in a series A round led by Perceptive Advisors and also gained rights to Leukine sargramostim from Sanofi (Euronext:SAN; NYSE:SNY). Fellow new investors Adams...
BC Extra | Feb 1, 2018
Company News

Roche halts SERD from Seragon, reports earnings

Roche (SIX:ROG; OTCQX:RHHBY) disclosed in its Thursday earnings report that it will discontinue development of RG6047 (GDC-0927). The selective estrogen receptor degrader was in a Phase I trial to treat ER-positive, HER2-negative metastatic breast cancer....
BC Extra | Jan 26, 2018
Company News

Management tracks: Partner Therapeutics, Merck

Robert Mulroy and Debasish Roychowdhury launched newco Partner Therapeutics Inc. (Boston, Mass.), which has a portfolio of approved and late-stage cancer therapies. Chairman and CEO Mulroy was co-founder, CEO and president of Merrimack Pharmaceuticals Inc....
BC Week In Review | Apr 28, 2017
Clinical News

RG6046: Development discontinued

Roche said it discontinued development of RG6046, which it gained through its acquisition of Seragon Pharmaceuticals Inc. in 2014. The pharma had studied RG6046 in a Phase II trial to treat estrogen receptor-positive, HER2-negative metastatic...
Items per page:
1 - 10 of 36